SecBot SecBot

SMTI

Sanara MedTech Inc.
Nasdaq· Orthopedic, Prosthetic & Surgical Appliances & Supplies· Inc. TX· CIK 0000714256 Healthcare & Medical Devices
$32.82 −0.20 (−0.61%)
Oct 27 4:00 PM ET · prev $33.02
Market cap
$301.4M
Small cap
Consensus
Sell
0% Buy or better · 8 analysts
Median target
$35.00
+7% · range $35.00–35.00
Next earnings
Nov 16
in 20 days · EPS est. $0.02
1 year
+7.6%
from $30.50 · Oct 27
30 days
−6.5%
from $35.10
52-week range
$16.34–35.28
−7% from high · low Mar 25
Avg volume 20D
185.1K
Oct 16 spike 741.6K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 1 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/6 ·Next Earnings date, Nov 16, 2026
Strongest BEARISH Sanara MedTech disclosed that it and MiMedx each received a Second Request from the FTC on October 15, 2026…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 12 added (0 new), 7 trimmed or exited.

  • AnalystsBEARISH

    0 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate $0.020 → $0.020 over 90 days.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD194,897$4.6M
GOLDMAN SACHS GROUP INCDOUBLED74,198$1.8M
Squarepoint Ops LLCTRIM53,811$1.3M
JANE STREET GROUP, LLCADD50,806$1.2M
MARSHALL WACE, LLPTRIM49,457$1.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD23,417$552.4K
HSBC HOLDINGS PLCADD23,254$549.7K
PRICE T ROWE ASSOCIATES INC /MD/ADD19,252$455.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold5Sell1Strong Sell2
12-month targets · 3 analysts

Price is below the lowest target. Median implies +7%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jul 30, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Jun 17, 2026Freedom Broker
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 15, 2026
Yon Seth D
Chief Executive Officer
TAX W/H$128.5K
Jun 4, 2026
Myers Keith G
Director
AWARD4,385 sh
Jun 4, 2026
Salamone Ann Beal
Director
AWARD4,154 sh
Jun 4, 2026
Ortwein Sara N
Director
AWARD4,616 sh
Jun 4, 2026
Mack Roszell III
Director
AWARD5,308 sh
Jun 4, 2026
DeSutter Robert Andrew
Director
AWARD5,539 sh
Jun 4, 2026
Nixon Ronald T
Director
AWARD4,154 sh
Jun 4, 2026
TANZBERGER ERIC D
Director
AWARD5,308 sh

Earnings setup

Estimates
Nov 16
reports in 20 days
$0.02
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.02$0.02–$0.02+0.0%$29.5M
Next Q$0.18$0.18–$0.18+0.0%$31.2M
Current FY$0.20$0.20–$0.20+11.1%$116.6M
Next FY$0.54$0.54–$0.54+0.0%$133.2M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 29, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
Sanara MedTech disclosed that it and MiMedx each received a Second Request from the FTC on October 15, 2026, extending…
425 — Impact 6/10
Oct 16, 2026 SEC
Sanara MedTech and MiMedx each received a Second Request from the FTC on October 15, 2026, extending the HSR Act…
8-K — Impact 4/10
Sep 15, 2026 Insider
Yon Seth D surrendered for taxes 3,661 shares
Chief Executive Officer @ $35.11 ($128.5K)
Aug 17, 2026 Earnings calendar
SMTI Q2 2026 Earnings Scheduled — 2026-08-17
Jul 30, 2026 SEC
Sanara MedTech filed a routine 425 communication (LinkedIn post) reiterating the previously announced definitive…
425 — Impact 3/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
194,897 shares ($4.6M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
74,198 shares ($1.8M)
Jun 4, 2026 Insider
Myers Keith G was granted 4,385 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
SMTI Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Aug 17, 2026
Earnings date
SMTI Q2 2026 Earnings Scheduled — 2026-08-17
Aug 11, 2026
Earnings date
SMTI Q2 2026 Earnings Scheduled — 2026-08-11
Jul 30, 2026
Press release
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)
NEW YORK, July 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has…
Jul 30, 2026
Press release
Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Sanara (Nasdaq: SMTI) for possible breaches of fiduciary duty and other…
Jul 29, 2026
Trading halt
Halt Resumed: SMTI — trading resumed after T3 (News and Resumption Times)
Halted 2026-07-29T18:21:10.000Z | Resumed 2026-07-29T20:30:00.000Z

SecBot reports

11 filings · 1 press release · 2 bullish · 1 bearish · 8 neutral
All SMTI filing & press-release reports (12)